Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. OS Therapies NYSE:OSTX$1.75 -0.03 (-1.69%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.01 (+0.86%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$49.17 millionP/E Ratio-2.03Consensus RatingBuyConsensus Price Target$18.00 (+928.6% Upside)Volume297,148 sharesAverage Volume736,787 shares Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Western Copper & Gold NYSE:WRN$1.20 -0.03 (-2.44%) As of 04:00 PM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$240.90 millionP/E Ratio-60.00Consensus RatingBuyConsensus Price Target$4.00 (+233.3% Upside)Volume147,292 sharesAverage Volume369,349 shares3. Quince Therapeutics NASDAQ:QNCX$1.68 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$1.65 -0.03 (-1.79%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$90.62 millionConsensus RatingBuyConsensus Price Target$8.00 (+376.2% Upside)Volume61,019 sharesAverage Volume204,968 sharesToday's Range$1.63▼$1.704. Reviva Pharmaceuticals NASDAQ:RVPH$0.44 -0.03 (-6.90%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.78%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$22.46 millionConsensus RatingBuyConsensus Price Target$9.00 (+1,966.1% Upside)Volume1.75 million sharesAverage Volume2.97 million sharesToday's Range$0.42▼$0.465. Immunic NASDAQ:IMUX$0.93 -0.01 (-0.91%) Closing price 04:00 PM EasternExtended Trading$0.94 +0.01 (+0.81%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$90.08 millionConsensus RatingBuyConsensus Price Target$7.50 (+705.2% Upside)Volume668,229 sharesAverage Volume1.07 million sharesToday's Range$0.89▼$0.936. Ovid Therapeutics NASDAQ:OVID$0.50 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$0.50 +0.00 (+0.60%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid TherapeuticsMarket Capitalization$35.56 millionConsensus RatingBuyConsensus Price Target$3.13 (+525.0% Upside)Volume535,545 sharesAverage Volume2.52 million sharesToday's Range$0.48▼$0.517. Ur Energy NYSEAMERICAN:URG$1.16 -0.05 (-4.13%) Closing price 04:10 PM EasternExtended Trading$1.16 +0.01 (+0.43%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$441.43 millionConsensus RatingBuyConsensus Price Target$2.48 (+113.4% Upside)Volume3.57 million sharesAverage Volume5.43 million sharesToday's Range$1.13▼$1.198. Lucid Diagnostics NASDAQ:LUCD$1.00 +0.02 (+2.19%) Closing price 04:00 PM EasternExtended Trading$1.02 +0.02 (+2.50%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$105.87 millionConsensus RatingBuyConsensus Price Target$3.55 (+255.0% Upside)Volume725,262 sharesAverage Volume984,937 sharesToday's Range$0.95▼$1.019. Stardust Power NASDAQ:SDST$0.41 -0.01 (-2.32%) Closing price 04:00 PM EasternExtended Trading$0.40 -0.01 (-1.65%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$25.63 millionConsensus RatingBuyConsensus Price Target$5.11 (+1,141.5% Upside)Volume1.33 million sharesAverage Volume25.72 million sharesToday's Range$0.39▼$0.4310. Mereo BioPharma Group NASDAQ:MREO$1.66 -0.03 (-1.78%) Closing price 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.66%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma GroupMarket Capitalization$268.71 millionConsensus RatingBuyConsensus Price Target$7.20 (+333.7% Upside)Volume1.03 million sharesAverage Volume4.47 million sharesToday's Range$1.65▼$1.7111. FibroBiologics NASDAQ:FBLG$0.65 +0.01 (+1.82%) Closing price 04:00 PM EasternExtended Trading$0.64 -0.01 (-1.17%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$25.28 millionConsensus RatingBuyConsensus Price Target$13.00 (+1,904.3% Upside)Volume746,797 sharesAverage Volume458,093 sharesToday's Range$0.60▼$0.6612. Biomea Fusion NASDAQ:BMEA$1.57 -0.09 (-5.42%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.07 (+4.71%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$62.37 millionConsensus RatingBuyConsensus Price Target$20.10 (+1,180.3% Upside)Volume1.06 million sharesAverage Volume904,454 sharesToday's Range$1.53▼$1.6513. Context Therapeutics NASDAQ:CNTX$0.71 -0.02 (-2.74%) Closing price 04:00 PM EasternExtended Trading$0.71 +0.00 (+0.28%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$65.48 millionConsensus RatingBuyConsensus Price Target$5.50 (+674.6% Upside)Volume119,312 sharesAverage Volume196,248 sharesToday's Range$0.70▼$0.7714. Gain Therapeutics NASDAQ:GANX$1.44 -0.02 (-1.37%) Closing price 04:00 PM EasternExtended Trading$1.47 +0.03 (+2.36%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$43.90 millionConsensus RatingBuyConsensus Price Target$8.20 (+469.4% Upside)Volume246,306 sharesAverage Volume263,875 sharesToday's Range$1.41▼$1.5215. Zura Bio NASDAQ:ZURA$1.50 +0.10 (+7.14%) Closing price 04:00 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More about Zura BioMarket Capitalization$95.72 millionConsensus RatingBuyConsensus Price Target$14.33 (+855.6% Upside)Volume471,118 sharesAverage Volume966,579 sharesToday's Range$1.35▼$1.5216. Aclaris Therapeutics NASDAQ:ACRS$1.53 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.65%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris TherapeuticsMarket Capitalization$165.67 millionConsensus RatingBuyConsensus Price Target$8.71 (+469.6% Upside)Volume1.09 million sharesAverage Volume1.33 million sharesToday's Range$1.50▼$1.5917. Adicet Bio NASDAQ:ACET$0.67 -0.02 (-2.19%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.03 (+4.53%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet BioMarket Capitalization$56.71 millionP/E Ratio-0.52Consensus RatingBuyConsensus Price Target$6.00 (+794.7% Upside)Volume271,773 sharesAverage Volume355,689 shares18. Acrivon Therapeutics NASDAQ:ACRV$1.26 -0.02 (-1.56%) Closing price 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. More about Acrivon TherapeuticsMarket Capitalization$40.13 millionConsensus RatingBuyConsensus Price Target$17.71 (+1,305.9% Upside)Volume140,802 sharesAverage Volume280,616 sharesToday's Range$1.21▼$1.2919. Erasca NASDAQ:ERAS$1.39 -0.03 (-1.77%) Closing price 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. More about ErascaMarket Capitalization$400.85 millionP/E Ratio-2.24Consensus RatingBuyConsensus Price Target$4.57 (+228.9% Upside)Volume804,375 sharesAverage Volume812,222 shares20. Cresco Labs OTCMKTS:CRLBF$0.62 +0.03 (+4.48%) As of 03:59 PM EasternCresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco LabsMarket Capitalization$291.37 millionConsensus RatingBuyVolume1.30 million sharesAverage Volume798,477 sharesToday's Range$0.57▼$0.6650-Day Range$0.43▼$0.7021. Lineage Cell Therapeutics NYSEAMERICAN:LCTX$0.99 -0.03 (-3.40%) Closing price 04:10 PM EasternExtended Trading$1.00 +0.02 (+1.80%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell TherapeuticsMarket Capitalization$232.92 millionConsensus RatingBuyConsensus Price Target$4.20 (+326.3% Upside)Volume2.00 million sharesAverage Volume1.55 million sharesToday's Range$0.96▼$1.0422. TScan Therapeutics NASDAQ:TCRX$1.62 -0.12 (-6.90%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.05 (-2.78%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. More about TScan TherapeuticsMarket Capitalization$98.47 millionConsensus RatingBuyConsensus Price Target$7.80 (+381.5% Upside)Volume462,376 sharesAverage Volume313,221 sharesToday's Range$1.60▼$1.7723. Century Therapeutics NASDAQ:IPSC$0.53 -0.02 (-2.87%) Closing price 04:00 PM EasternExtended Trading$0.53 +0.00 (+0.21%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More about Century TherapeuticsMarket Capitalization$47.18 millionConsensus RatingBuyConsensus Price Target$4.20 (+689.6% Upside)Volume710,670 sharesAverage Volume1.05 million sharesToday's Range$0.52▼$0.5724. Tenaya Therapeutics NASDAQ:TNYA$0.67 -0.01 (-0.80%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.01 (+1.25%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya TherapeuticsMarket Capitalization$109.96 millionConsensus RatingBuyConsensus Price Target$6.25 (+832.0% Upside)Volume1.57 million sharesAverage Volume2.36 million sharesToday's Range$0.64▼$0.6925. Cabaletta Bio NASDAQ:CABA$1.44 -0.08 (-5.26%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.05 (+3.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More about Cabaletta BioMarket Capitalization$77.13 millionConsensus RatingBuyConsensus Price Target$14.43 (+902.0% Upside)Volume935,451 sharesAverage Volume1.15 million sharesToday's Range$1.43▼$1.55 More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
